HCA HCA Healthcare, Inc. Common Stock
关于 HCA Healthcare, Inc. Common Stock 公司概况(来自维基百科)
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
阅读更多
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was serving as chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
HCA 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
HCA 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
股息 收益率、派息率、股息历史、5年CAGR
| 除息日 | 金额 |
|---|---|
| 2026年6月16日 | $0.7800 |
| 2026年3月17日 | $0.7800 |
| 2025年12月15日 | $0.7200 |
| 2025年9月16日 | $0.7200 |
| 2025年6月16日 | $0.7200 |
| 2025年3月17日 | $0.7200 |
| 2024年12月13日 | $0.6600 |
| 2024年9月16日 | $0.6600 |
| 2024年6月14日 | $0.6600 |
| 2024年3月14日 | $0.6600 |
| 2023年12月13日 | $0.6000 |
| 2023年9月14日 | $0.6000 |
| 2023年6月15日 | $0.6000 |
| 2023年3月16日 | $0.6000 |
| 2022年12月13日 | $0.5600 |
| 2022年9月15日 | $0.5600 |
| 2022年6月15日 | $0.5600 |
| 2022年3月16日 | $0.5600 |
| 2021年12月13日 | $0.4800 |
| 2021年9月15日 | $0.4800 |
HCA 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 6 20.0%
- 买入 11 36.7%
- 持有 12 40.0%
- 卖出 1 3.3%
- 强烈卖出 0 0.0%
12个月价格目标
21 位分析师 · 2026-08-17收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $7.62 | $7.54 | 0.08% |
| 2026年3月31日 | $7.15 | $7.21 | -0.06% |
| 2025年12月31日 | $8.14 | $7.53 | 0.61% |
| 2025年9月30日 | $6.96 | $5.77 | 1.2% |
| 2025年6月30日 | $6.83 | $6.31 | 0.52% |
| 2025年3月31日 | $6.45 | $5.84 | 0.61% |
同行比较(GICS 子行业) 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | — |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | — |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | — |
| UHS | — | 9.4 | 9.7% | 8.6% | 21.4% | — |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | — |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | — |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | — |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 12
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
资产负债表 22
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
现金流 17
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
盈利能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
流动性与偿付能力 4
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
增长率 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
估值 (TTM) 17
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
损益表 12
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | -482,587,000 | 232,891,000 | 239,173,000 | 246,936,000 | -523,751,000 | 256,763,000 | 261,156,000 | 264,435,000 | -550,173,000 | 271,173,000 | 274,494,000 | 276,910,000 | -590,583,000 | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | -488,037,000 | 236,181,000 | 241,911,000 | 249,440,000 | -530,198,000 | 259,917,000 | 264,071,000 | 268,016,000 | -558,171,000 | 275,424,000 | 278,198,000 | 280,961,000 | -598,621,000 | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
资产负债表 20
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
现金流 16
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
流动性与偿付能力 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
估值 (TTM) 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $77.11B | $75.20B | · | $73.57B | $71.91B | $70.64B | · | $68.53B | $66.91B | $65.00B | · | $62.64B | $61.24B | $60.33B | · | $60.01B | |
| Net Income TTM | $6.62B | $6.53B | · | $6.18B | $5.99B | $5.93B | · | $5.40B | $5.32B | $5.23B | · | $4.77B | $4.84B | $4.92B | · | $5.83B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.7 | 17.3 | · | 17.0 | 16.2 | 15.2 | · | 20.1 | 16.3 | 17.6 | · | 14.5 | 17.9 | 15.7 | · | 9.7 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.3 | 1.2 | · | 1.5 | 1.2 | 1.4 | · | 1.1 | 1.4 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| P / FCF | · | 117.7 | · | · | · | 127.2 | · | · | · | 65.0 | · | · | · | 120.1 | · | · | |
| EV / EBITDA | 135.0 | 154.7 | · | 152.3 | 149.4 | 148.2 | · | 170.5 | 150.6 | 159.4 | · | 136.0 | 158.5 | 146.5 | · | 118.7 | |
| EV / FCF | · | 160.7 | · | · | · | 193.1 | · | · | · | 93.8 | · | · | · | 182.8 | · | · | |
| EV / Revenue | 1.7 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Earnings Yield | 7.3% | 5.8% | · | 5.9% | 6.2% | 6.6% | · | 5.0% | 6.1% | 5.7% | · | 6.9% | 5.6% | 6.4% | · | 10.3% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| 净收入 | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| 稀释后每股收益 (EPS) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| 流动比率 | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| 速动比率 | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
最新新闻 提及该公司的近期头条新闻
- Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
- HCA Healthcare (HCA) Reports Q1 2026 Financial Growth With $19.1B in Revenue
- 值得关注的星期四期权活动:HCA、HRTG、ZM
- HCA Healthcare (HCA) 融资策略扩展 – 了解详情
- HCA Healthcare 医疗保健公司季度利润超出预期,得益于医疗需求
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存,并会跟随您浏览所有股票。
机构持有人 (13F) 1485 家申报者 · $39.4B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 128 (-51 与上一季度对比) | 174 (+70 与上一季度对比) | 450 (-30 与上一季度对比) | 555 (-4 与上一季度对比) | +16.3M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
公司内部人士 91 位内幕人士 · 54 位高管 · 31 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 2026年2月10日 F | 64842 | 0 | 7 | $-21483290 |
| O'Boyle Michael P | President & CEO - Parallon | 2013年2月26日 A | 21429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 2026年5月7日 G | 46576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 2024年2月16日 F | 22251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 2006年11月17日 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 2005年7月1日 F | 13865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 2024年11月12日 M | 6843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 2024年7月31日 M | 27008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 2024年2月16日 F | 17936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 2022年11月11日 M | 202443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 2022年11月11日 S | 30807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 2012年12月31日 A | 335657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2011年11月2日 M | 144714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 2006年7月26日 A | 62173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 2005年10月27日 A | 26154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 2004年10月31日 D | 9029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 2004年5月7日 D | 24177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 2026年2月10日 F | 23062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 2026年2月13日 M | 8853 | 0 | 2 | $-2747520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 2026年2月11日 S | 11993 | 0 | 2 | $-4126932 |
| Christopher F. Wyatt | SVP & Controller | 2026年2月11日 S | 44379 | 0 | 1 | $-2020000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 2026年2月10日 F | 10407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 2026年2月10日 F | 32080 | 0 | 1 | $-747135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 2025年2月13日 F | 11113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 2024年11月14日 S | 9454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 2024年11月12日 M | 52702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 2024年8月5日 G | 18526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 2024年7月29日 S | 3510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 2024年7月25日 S | 17755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 2024年5月9日 S | 5185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 2024年3月18日 M | 1576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 2023年4月12日 M | 24643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 2021年11月9日 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 2021年5月5日 S | 50062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 2021年2月18日 F | 5578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 2021年2月18日 F | 10122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 2019年5月1日 A | 194145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 2019年2月25日 M | 84157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 2019年2月25日 M | 881823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 2018年2月25日 M | 7003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 2018年2月25日 M | 35546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 2018年2月25日 M | 65199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 2017年5月23日 M | 26378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 2016年11月7日 M | 110167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 2016年2月25日 A | 51965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 2012年5月16日 M | 299030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 2009年10月6日 A | 188340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 2009年2月27日 M | 13092 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
激进投资者及 5%+ 股东 4 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 2026年2月10日 | 31.60% | 初始申报 | — | SEC |
| 2006年11月22日 | — | 初始申报 | — | SEC | |
| Merrill Lynch Bank USA | 2006年9月11日 | — | 初始申报 | — | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 2006年8月4日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 207 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IHF · iShares Trust | 4.67% | 141320 SH | 2026年8月8日 | 每日 |
| BUL · Pacer Funds Trust | 3.91% | 11437 NS | 2026年4月30日 | N-PORT |
| YALL · Tidal Trust I | 3.61% | 9261 NS | 2026年5月31日 | N-PORT |
| BWTG · ETF Opportunities Trust | 3.02% | 1646 NS | 2026年5月31日 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2.32% | 99335 SH | 2026年8月8日 | 每日 |
| ABIG · EA Series Trust | 2.00% | 2938 NS | 2026年5月29日 | N-PORT |
| FXH · First Trust Exchange-Traded Alpha... | 1.99% | 39985 NS | 2026年4月30日 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.67% | 31685 SH | 2026年8月8日 | 每日 |
| COWZ · Pacer Funds Trust | 1.64% | 688264 NS | 2026年4月30日 | N-PORT |
| QQWZ · Pacer Funds Trust | 1.64% | 1762 NS | 2026年4月30日 | N-PORT |
| FEGE · RBB Fund Trust | 1.46% | 74706 NS | 2026年5月31日 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1.39% | 60385 SH | 2026年8月8日 | 每日 |
| RPG · Invesco Exchange-Traded Fund Trust | 1.30% | 63448 SH | 2026年8月8日 | 每日 |
| TMFE · RBB Fund, Inc. | 1.29% | 2892 NS | 2026年5月31日 | N-PORT |
| AMID · EA Series Trust | 1.23% | 3402 NS | 2026年5月29日 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.15% | 7180 NS | 2026年4月30日 | N-PORT |
| FMAG · FIDELITY COVINGTON TRUST | 1.12% | 6544 NS | 2026年4月30日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1.12% | 73639 NS | 2026年4月30日 | N-PORT |
| SRHQ · Elevation Series Trust | 1.10% | 4883 NS | 2026年4月30日 | N-PORT |
| IYH · iShares Trust | 0.99% | 89420 SH | 2026年8月8日 | 每日 |
| NEAR · iShares U.S. ETF Trust | 0.99% | 48109000 SH | 2026年8月8日 | 每日 |
| CURE · Direxion Shares ETF Trust | 0.98% | 3122 NS | 2026年4月30日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.90% | 470451 SH | 2026年8月8日 | 每日 |
| NFRA · FlexShares Trust | 0.88% | 62176 NS | 2026年4月30日 | N-PORT |
| REVS · Columbia ETF Trust I | 0.87% | 5693 NS | 2026年4月30日 | N-PORT |
| RXL · ProShares Trust | 0.86% | 1632 NS | 2026年5月31日 | N-PORT |
| DIVB · iShares Trust | 0.85% | 36806 SH | 2026年8月8日 | 每日 |
| BSCT · Invesco Exchange-Traded Self-Inde... | 0.82% | 24078000 | 2026年8月8日 | 每日 |
| LSEQ · Harbor ETF Trust | 0.81% | 285 NS | 2026年4月30日 | N-PORT |
| IXJ · iShares Trust | 0.80% | 81465 SH | 2026年8月8日 | 每日 |
| BSCS · Invesco Exchange-Traded Self-Inde... | 0.76% | 26493000 | 2026年8月8日 | 每日 |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.74% | 2335 SH | 2026年8月8日 | 每日 |
| FTC · First Trust Exchange-Traded Alpha... | 0.73% | 21329 NS | 2026年4月30日 | N-PORT |
| RFFC · ALPS ETF Trust | 0.68% | 533 NS | 2026年5月31日 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.68% | 2698 NS | 2026年4月30日 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.67% | 12075 SH | 2026年8月8日 | 每日 |
| VCEB · VANGUARD WORLD FUND | 0.62% | 8146000 PA | 2026年8月8日 | 每日 |
| FDMO · FIDELITY COVINGTON TRUST | 0.61% | 11771 NS | 2026年4月30日 | N-PORT |
| RECS · Columbia ETF Trust I | 0.58% | 72768 NS | 2026年4月30日 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund ... | 0.56% | 9664 NS | 2026年5月31日 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.55% | 11876 SH | 2026年8月8日 | 每日 |
| VLLU · Harbor ETF Trust | 0.54% | 54 NS | 2026年4月30日 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.53% | 7404 NS | 2026年4月30日 | N-PORT |
| WLDR · Two Roads Shared Trust | 0.51% | 844 NS | 2026年4月30日 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 0.50% | 4620 NS | 2026年5月31日 | N-PORT |
| AKAF · ETF Series Solutions | 0.50% | 39 NS | 2026年5月31日 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Inde... | 0.50% | 22679000 | 2026年8月8日 | 每日 |
| ROUS · Lattice Strategies Trust | 0.47% | 6388 NS | 2026年4月30日 | N-PORT |
| VCLT · VANGUARD SCOTTSDALE FUNDS | 0.46% | 54218000 PA | 2026年8月8日 | 每日 |
| CGGR · Capital Group Growth ETF | 0.45% | 290273 NS | 2026年5月31日 | N-PORT |